Efficacy and Safety of DHEA for Myotonic Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00167609

Recruitment Status : Completed

First Posted : September 14, 2005

Last Update Posted : April 6, 2010

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Association Française contre les Myopathies (AFM), Paris

Assistance Publique - Hôpitaux de Paris

Information provided by:

University of Versailles

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Primary Completion Date :	No date given
Actual Study Completion Date :	December 2006

Publications of Results:

Penisson-Besnier I, Devillers M, Porcher R, Orlikowski D, Doppler V, Desnuelle C, Ferrer X, Bes MC, Bouhour F, Tranchant C, Lagrange E, Vershueren A, Uzenot D, Cintas P, Sole G, Hogrel JY, Laforet P, Vial C, Vila AL, Sacconi S, Pouget J, Eymard B, Chevret S, Annane D. Dehydroepiandrosterone for myotonic dystrophy type 1. Neurology. 2008 Aug 5;71(6):407-12. doi: 10.1212/01.wnl.0000324257.35759.40.

To Top